Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 19, Number 5—May 2013
Dispatch

Treatment of Tularemia in Patient with Chronic Graft-versus-Host Disease

Jan WeileComments to Author , Erik Seibold, Cornelius Knabbe, Martin Kaufmann, and Wolf Splettstoesser
Author affiliations: Heart and Diabetes Centre North Rhine–Westphalia, Bad Oeynhausen, Germany (J. Weile, C. Knabbe); Bundeswehr Institute of Microbiology, Munich, Germany (E. Seibold, W. Splettstoesser); University of Rostock, Rostock, Germany (W. Splettstoesser); Robert-Bosch-Hospital, Stuttgart, Germany (M. Kaufmann)

Main Article

Table

Susceptibility testing of the blood culture isolate (Francisella tularensis subsp. holarctica) break point analysis according to CLSI standard*

Antimicrobial agent MIC, mg/L Interpretation
Tetracycline 1.0 S
Ciprofloxacin 0.125 S
Levofloxacin 0.25 S
Chloramphenicol 2 S
Gentamicin 0.5 S
Streptomycin 2 S

*CLSI, Clinical and Laboratory Standards Institute; S, susceptible; R, resistant.

Main Article

Page created: April 03, 2013
Page updated: April 03, 2013
Page reviewed: April 03, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external